Home › Research › Drug development
Evaluation of Small-Animal PET Outcome Measures to Detect Disease Modification Induced by BACE Inhibition in a Transgenic Mouse Model of Alzheimer Disease
Deleye S, Waldron AM, Verhaeghe J, Bottelbergs A, Wyffels L, Van Broeck B, Langlois X, Schmidt M et al.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017-06-13
Topic: Brain proteins, microglia and lab models
Plain-language summary
In this study, we investigated the effects of chronic administration of an inhibitor of the β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) on Alzheimer-related pathology by multitracer PET imaging in transgenic APPPS1-21 (TG) mice. Methods: Wild-type (WT) and TG mice received vehicle or BACE inhibitor (60 mg/kg) starting at 7 wk of age. Outcome measures of brain metabolism, neuroinflammation, and amyloid-β pathology were obtained through small-animal PET imaging with 18 F-FDG, 18 F-peripheral benzodiazepine receptor ( 18 F-PBR), and 18 F-florbetapir ( 18 F-AV45), respectively.
What this study adds
Evidence grade: Low
This study used small-animal PET imaging to investigate the effects of chronic BACE1 inhibitor administration on Alzheimer-related pathology in transgenic mice. This is animal research, so it does not yet show whether BACE inhibition modifies disease in people.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Deleye, S., Waldron, A. M., Verhaeghe, J., Bottelbergs, A., Wyffels, L., Van Broeck, B., et al. (2017). Evaluation of Small-Animal PET Outcome Measures to Detect Disease Modification Induced by BACE Inhibition in a Transgenic Mouse Model of Alzheimer Disease. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. https://doi.org/10.2967/jnumed.116.187625
Vancouver
Deleye S, Waldron AM, Verhaeghe J, Bottelbergs A, Wyffels L, Van Broeck B, et al. Evaluation of Small-Animal PET Outcome Measures to Detect Disease Modification Induced by BACE Inhibition in a Transgenic Mouse Model of Alzheimer Disease. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2017. doi:10.2967/jnumed.116.187625. PMID: 28611242.
BibTeX
@article{deleye2017-28611242,
author = {Deleye, S. and Waldron, A. M. and Verhaeghe, J. and Bottelbergs, A. and Wyffels, L. and Van Broeck, B. and Langlois, X. and Schmidt, M. and others},
title = {{Evaluation of Small-Animal PET Outcome Measures to Detect Disease Modification Induced by BACE Inhibition in a Transgenic Mouse Model of Alzheimer Disease}},
journal = {Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
year = {2017},
doi = {10.2967/jnumed.116.187625},
pmid = {28611242},
url = {https://doi.org/10.2967/jnumed.116.187625}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Methods: Wild-type (WT) and TG mice received vehicle or BACE inhibitor (60 mg/kg) starting at 7 wk of age.
- Outcome measures of brain metabolism, neuroinflammation, and amyloid-β pathology were obtained through small-animal PET imaging with 18 F-FDG, 18 F-peripheral benzodiazepine receptor ( 18 F-PBR), and 18 F-florbetapir ( 18 F-AV45), respectively.
- Baseline scans were acquired at 6-7 wk of age and follow-up scans at 4, 7, and 12 mo. 18 F-AV45 uptake was measured at 8 and 13 mo of age.
- After the final scans, histologic measures of amyloid-β (4G8), microglia (ionized calcium binding adaptor molecule 1), astrocytes (glial fibrillary acidic protein), and neuronal nuclei were performed.
Why it matters
This study used small-animal PET imaging to investigate the effects of chronic BACE1 inhibitor administration on Alzheimer-related pathology in transgenic mice. This is animal research, so it does not yet show whether BACE inhibition modifies disease in people.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 36/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of nuclear medicine : official publication, Society of Nuclear Medicine) |
| Journal's citation record | 2 / 4 | Journal of Nuclear Medicine: journal h-index 230 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2017 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Laboratory or animal study (title names “transgenic”) — scores zero |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 26 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.4 citations a year over 11 year(s) since 2017 |
| Impact for its field and year | 2 / 6 | Cited 1.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 1 / 4 | Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Steven G. Staelens: h-index 39 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Antwerp: institution h-index 834 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 28611242) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 36 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.2967/jnumed.116.187625
- PubMed: 28611242
- Original source →
- Free full text: Journal of Nuclear Medicine →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
2 studies in the alzhub library list this one in their references. Showing the 1 highest-scoring.
Related studies in Drug development from nearby years
Also tagged “machine”
834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.